Lung cancer

ENCO-BRAF (IFCT-1904)

A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer

Open at Paris since : 02/03/2022
Target : Adult
Phase : Phase II

Trial description

Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

Url of the trial

Main investigator

CLEMENCE BASSE

Médecin

Contact